Abstract
The use and overall benefit of non-insulin glucose lowering agents for hospitalized patients is unclear due to limited data. Our study aims to determine the impact and safety of GLP-1 receptor agonist therapy in hospitalized diabetes patients with chronic kidney disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
